A61K 31/635
Having a heterocyclic ring
Official title: having a heterocyclic ring, e.g. sulfadiazine
A61K31/635 (Having a heterocyclic ring) appears on 860 US grants and 1,655 published applications in this corpus.
Search patents in A61K- Granted patents
- 860
- Published applications
- 1,655
- Assignees
- 796
- Inventors
- 3,691
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 4 | 0 |
| 1977 | 7 | 0 |
| 1978 | 8 | 0 |
| 1979 | 1 | 0 |
| 1980 | 2 | 0 |
| 1981 | 6 | 0 |
| 1982 | 7 | 0 |
| 1983 | 7 | 0 |
| 1984 | 2 | 0 |
| 1985 | 2 | 0 |
| 1986 | 4 | 0 |
| 1987 | 6 | 0 |
| 1988 | 2 | 0 |
| 1989 | 7 | 0 |
| 1990 | 5 | 0 |
| 1991 | 2 | 0 |
| 1992 | 3 | 0 |
| 1993 | 5 | 0 |
| 1994 | 5 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 7 | 0 |
| 1998 | 8 | 0 |
| 1999 | 12 | 0 |
| 2000 | 3 | 0 |
| 2001 | 7 | 4 |
| 2002 | 5 | 13 |
| 2003 | 7 | 26 |
| 2004 | 10 | 25 |
| 2005 | 5 | 23 |
| 2006 | 1 | 22 |
| 2007 | 5 | 18 |
| 2008 | 4 | 12 |
| 2009 | 6 | 14 |
| 2010 | 6 | 32 |
| 2011 | 12 | 27 |
| 2012 | 10 | 32 |
| 2013 | 31 | 53 |
| 2014 | 29 | 59 |
| 2015 | 32 | 90 |
| 2016 | 55 | 107 |
| 2017 | 66 | 96 |
| 2018 | 68 | 89 |
| 2019 | 56 | 104 |
| 2020 | 51 | 81 |
| 2021 | 38 | 107 |
| 2022 | 43 | 153 |
| 2023 | 40 | 143 |
| 2024 | 49 | 125 |
| 2025 | 55 | 103 |
| 2026 | 49 | 97 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Compositions for the treatment of rheumatoid arthritis and methods of using same29 Sep 2026US 12,747,487 B2Regeneron Pharmaceuticals, Inc.
- Short conjugated oligoelectrolytesand antibiotics22 Sep 2026US 12,740,950 B2Nanyang Technological University
- Methods for preparing liposomal formulations15 Sep 2026US 12,734,181 B2Jazz Pharmaceuticals Therapeutics, Inc.
- Treatment of immunosuppressed subjects15 Sep 2026US 12,734,216 B2NantCell, Inc.
- Liquisolid pharmaceutical formulation and process for manufacturing8 Sep 2026US 12,728,134 B2Rheinische Friedrich-Wilhelms-Universität Bonn
- Prolyl hydroxylase domain-containing protein (phd) inhibitors, combinations and uses thereof8 Oct 2026US 2026/0306471 A1Insilico Medicine IP Limited
- Combination therapy with clk/dyrk inhibitors and bcl2 inhibitors to treat leukemia8 Oct 2026US 2026/0306486 A1BioSplice Therapeutics, Inc.
- Oral pharmaceutical formulations containing 4-((2-hydroxy-3-methoxybenzyl)amino) benzenesulfonamide derivatives8 Oct 2026US 2026/0306514 A1Cadrenal Therapeutics, Inc.
- Cdk2 inhibitors and methods of using same8 Oct 2026US 2026/0308145 A1Guangdong Touchstone Translational Research Institute Co., Ltd.
- Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs1 Oct 2026US 2026/0295040 A1Merus N.V.
Most cited
By later US patents
- Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers124US 6,045,829 AElan Pharma International Limited · 2000
- Multi-particulate form of medicament, comprising at least two differently coated forms of pellet111US 6,897,205 B2Roehm GmbH · 2005
- Treatment of non-inflammatory and non-infectious bowel disorders103US 5,519,014 A1996
- Prodrugs of benzenesulfonamide-containing COX-2 inhibitors86US 5,932,598 AG. D. Searle & Co. · 1999
- Controlled-release mucoadhesive pharmaceutical composition for the oral administration of furosemide85US 5,571,533 ARecordati S.A., Chemical and Pharmaceutical Company · 1996